114 related articles for article (PubMed ID: 30929381)
1. [How I treat primary myelofibrosis].
Xiao ZJ
Zhonghua Xue Ye Xue Za Zhi; 2019 Mar; 40(3):179-181. PubMed ID: 30929381
[No Abstract] [Full Text] [Related]
2. The evolution and clinical relevance of prognostic classification systems in myelofibrosis.
Bose P; Verstovsek S
Cancer; 2016 Mar; 122(5):681-92. PubMed ID: 26717494
[TBL] [Abstract][Full Text] [Related]
3. Systemic lupus erythematosus presenting with myelofibrosis.
Foley-Nolan D; Martin MF; Rowbotham D; McVerry A; Gooi HC
J Rheumatol; 1992 Aug; 19(8):1303-4. PubMed ID: 1404171
[TBL] [Abstract][Full Text] [Related]
4. Construction of gene/protein interaction networks for primary myelofibrosis and KEGG pathway-enrichment analysis of molecular compounds.
Sun CG; Cao XJ; Zhou C; Liu LJ; Feng FB; Liu RJ; Zhuang J; Li YJ
Genet Mol Res; 2015 Dec; 14(4):16126-32. PubMed ID: 26662404
[TBL] [Abstract][Full Text] [Related]
5. Primary autoimmune myelofibrosis: a case report and review of the literature.
Abaza Y; Yin CC; Bueso-Ramos CE; Wang SA; Verstovsek S
Int J Hematol; 2017 Apr; 105(4):536-539. PubMed ID: 27830539
[TBL] [Abstract][Full Text] [Related]
6. β-Arrestin2 mediates progression of murine primary myelofibrosis.
Rein LA; Wisler JW; Kim J; Theriot B; Huang L; Price T; Yang H; Chen M; Chen W; Sipkins D; Fedoriw Y; Walker JK; Premont RT; Lefkowitz RJ
JCI Insight; 2017 Dec; 2(24):. PubMed ID: 29263312
[TBL] [Abstract][Full Text] [Related]
7. OCULAR MANIFESTATIONS OF PRIMARY MYELOFIBROSIS.
Lin AL; Burnham JM; Pang V; Idowu O; Iyer S
Retin Cases Brief Rep; 2016; 10(4):364-7. PubMed ID: 26836259
[TBL] [Abstract][Full Text] [Related]
8. Osteogenic Potential of Mesenchymal Stromal Cells Contributes to Primary Myelofibrosis.
Martinaud C; Desterke C; Konopacki J; Pieri L; Torossian F; Golub R; Schmutz S; Anginot A; Guerton B; Rochet N; Albanese P; Henault E; Pierre-Louis O; Souraud JB; de Revel T; Dupriez B; Ianotto JC; Bourgeade MF; Vannucchi AM; Lataillade JJ; Le Bousse-Kerdilès MC
Cancer Res; 2015 Nov; 75(22):4753-65. PubMed ID: 26404004
[TBL] [Abstract][Full Text] [Related]
9. Tetraspanin CD9 participates in dysmegakaryopoiesis and stromal interactions in primary myelofibrosis.
Desterke C; Martinaud C; Guerton B; Pieri L; Bogani C; Clay D; Torossian F; Lataillade JJ; Hasselbach HC; Gisslinger H; Demory JL; Dupriez B; Boucheix C; Rubinstein E; Amsellem S; Vannucchi AM; Le Bousse-Kerdilès MC
Haematologica; 2015 Jun; 100(6):757-67. PubMed ID: 25840601
[TBL] [Abstract][Full Text] [Related]
10. Megakaryocytic morphology and clinical parameters in essential thrombocythemia, polycythemia vera, and primary myelofibrosis with and without JAK2 V617F.
Vytrva N; Stacher E; Regitnig P; Zinke-Cerwenka W; Hojas S; Hubmann E; Porwit A; Bjorkholm M; Hoefler G; Beham-Schmid C
Arch Pathol Lab Med; 2014 Sep; 138(9):1203-9. PubMed ID: 25171702
[TBL] [Abstract][Full Text] [Related]
11. The impact of cytogenetic abnormalities on the prognosis of primary myelofibrosis: a prospective survey of 202 cases in Japan.
Hidaka T; Shide K; Shimoda H; Kameda T; Toyama K; Katayose K; Kubuki Y; Nagata K; Takenaka K; Akashi K; Okamura T; Niho Y; Mizoguchi H; Omine M; Ozawa K; Harada M; Shimoda K
Eur J Haematol; 2009 Oct; 83(4):328-33. PubMed ID: 19549278
[TBL] [Abstract][Full Text] [Related]
12. Pacritinib to treat myelofibrosis patients with thrombocytopenia.
Tremblay D; Mascarenhas J
Expert Rev Hematol; 2018 Sep; 11(9):707-714. PubMed ID: 30001163
[TBL] [Abstract][Full Text] [Related]
13. [Clinical characteristics of primary myelofibrosis].
Simeonov Ts; Petrov I
Vutr Boles; 1979; 18(6):108-12. PubMed ID: 524867
[TBL] [Abstract][Full Text] [Related]
14. Pancytopenia and secondary myelofibrosis could be induced by primary hyperparathyroidism.
Lim DJ; Oh EJ; Park CW; Kwon HS; Hong EJ; Yoon KH; Kang MI; Cha BY; Lee KW; Son HY; Kang SK
Int J Lab Hematol; 2007 Dec; 29(6):464-8. PubMed ID: 17988303
[TBL] [Abstract][Full Text] [Related]
15. Austrian recommendations for the management of primary myelofibrosis, post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis: an expert statement.
Sliwa T; Beham-Schmid C; Burgstaller S; Buxhofer-Ausch V; Gastl G; Geissler K; Krauth M; Krippl P; Lang A; Petzer A; Wöhrer S; Wölfler A; Gisslinger H
Wien Klin Wochenschr; 2017 May; 129(9-10):293-302. PubMed ID: 27966016
[TBL] [Abstract][Full Text] [Related]
16. Immunoreactive prolyl hydroxylase in patients with primary and secondary myelofibrosis.
Wang JC; Wong C; Kao WW
Br J Haematol; 1987 Feb; 65(2):171-4. PubMed ID: 3030390
[TBL] [Abstract][Full Text] [Related]
17. Post-ET and Post-PV Myelofibrosis: Updates on a Distinct Prognosis from Primary Myelofibrosis.
Passamonti F; Mora B; Barraco D; Maffioli M
Curr Hematol Malig Rep; 2018 Jun; 13(3):173-182. PubMed ID: 29713873
[TBL] [Abstract][Full Text] [Related]
18. [18F-FDG-PET/CT is effective in distinguishing myelofibrosis due to bone marrow infiltration of diffuse large B-cell lymphoma from triple-negative primary myelofibrosis].
Kumagai T; Satoh Y; Koshiishi M; Ooishi S; Sueki Y; Nakajima K; Mitsumori T; Kirito K
Rinsho Ketsueki; 2017; 58(3):228-232. PubMed ID: 28381690
[TBL] [Abstract][Full Text] [Related]
19. Myelodysplastic syndrome with myelofibrosis: myelodysplastic syndrome as a major primary disorder for acute myelofibrosis.
Takahashi M; Koike T; Nagayama R; Fujiwara M; Koyama S; Ohnishi M; Nakamori Y; Soga N; Aoki S; Tatewaki W
Clin Lab Haematol; 1991; 13(1):17-23. PubMed ID: 2060260
[TBL] [Abstract][Full Text] [Related]
20. Myelofibrosis in primary myelodysplastic syndromes: a retrospective study of 352 patients.
Maschek H; Georgii A; Kaloutsi V; Werner M; Bandecar K; Kressel MG; Choritz H; Freund M; Hufnagl D
Eur J Haematol; 1992 Apr; 48(4):208-14. PubMed ID: 1592101
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
